- £181.66m
- £157.22m
- £56.04m
- 62
- 29
- 98
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.49 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -27.54% | ||
| Dividend Yield (f) | 0.87% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.29 | ||
| Price to Tang. Book | 6.34 | ||
| Price to Free Cashflow | 15.06 | ||
| Price to Sales | 3.24 | ||
| EV to EBITDA | 12.27 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.02% | ||
| Return on Equity | 59.09% | ||
| Operating Margin | 18.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 3.37 | 20.6 | 36.86 | 48.48 | 56.04 | 62.42 | 68.39 | 35.4% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | +320 | -39.49 | +17.64 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
Directors
- Cathal Friel CHM (56)
- Leo Toole CFO (48)
- Brendan Buckley NED (71)
- Elaine Sullivan NED (60)
- Yamin Mohammed Khan NID (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 2nd, 2011
- Public Since
- December 14th, 2012
- No. of Employees
- 274
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 680,371,877
- Address
- 42 New Road, LONDON, E1 2AX
- Web
- https://hvivo.com/
- Phone
- +44 2890737900
- Auditors
- Gravita Audit Limited
Latest News for HVO
Upcoming Events for HVO
hVIVO PLC Annual Shareholders Meeting
hVIVO PLC Annual Shareholders Meeting
Half Year 2024 hVIVO PLC Earnings Release
Similar to HVO
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 19:11 UTC, shares in hVIVO are trading at 26.70p. This share price information is delayed by 15 minutes.
Shares in hVIVO last closed at 26.70p and the price had moved by +49.18% over the past 365 days. In terms of relative price strength the hVIVO share price has outperformed the FTSE All Share Index by +49.24% over the past year.
The overall consensus recommendation for hVIVO is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The hVIVO dividend yield is 0.75% based on the trailing twelve month period.
Last year, hVIVO paid a total dividend of £0.00, and it currently has a trailing dividend yield of 0.75%.Looking ahead, the next dividend pay date is 2024-05-20.
We do not have data on when hVIVO is to next pay dividends. The historic dividend yield on hVIVO shares is currently 0.75%.
To buy shares in hVIVO you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 26.70p, shares in hVIVO had a market capitalisation of £181.66m.
Here are the trading details for hVIVO:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: HVO
Based on an overall assessment of its quality, value and momentum hVIVO is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in hVIVO is 36.29p. That is 35.91% above the last closing price of 26.70p.
Analysts covering hVIVO currently have a consensus Earnings Per Share (EPS) forecast of £0.01 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like hVIVO. Over the past six months, its share price has outperformed the FTSE All Share Index by +24.24%.
As of the last closing price of 26.70p, shares in hVIVO were trading +19.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The hVIVO PE ratio based on its reported earnings over the past 12 months is 17.49. The shares last closed at 26.70p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
hVIVO's management team is headed by:
- Cathal Friel - CHM
- Leo Toole - CFO
- Brendan Buckley - NED
- Elaine Sullivan - NED
- Yamin Mohammed Khan - NID